Eton Pharmaceuticals ( (ETON) ) has released its Q2 earnings. Here is a breakdown of the information Eton Pharmaceuticals presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Eton Pharmaceuticals is an innovative pharmaceutical company that focuses on developing and commercializing treatments for rare diseases. The company has a diverse portfolio of commercial products and is actively advancing several late-stage product candidates.
In its second quarter of 2025, Eton Pharmaceuticals reported significant financial growth, with product sales reaching $18.9 million, marking a 108% increase compared to the same period in the previous year. The company also launched KHINDIVI, the first FDA-approved oral solution of hydrocortisone, and surpassed its target of 100 active INCRELEX patients ahead of schedule.
Key financial highlights for the quarter include a gross profit of $11.9 million, an adjusted EBITDA of $3.1 million, and a non-GAAP net income of $1.5 million. The company’s revenue growth was primarily driven by the continued success of ALKINDI SPRINKLE and the relaunches of INCRELEX and GALZIN. Eton also reported a strong cash position with $25.4 million in cash and cash equivalents.
Looking ahead, Eton Pharmaceuticals anticipates reaching an annual revenue run rate of $80 million in the third quarter of 2025, one quarter ahead of its previous guidance. The company is also preparing for the potential approval and launch of ET-600 in early 2026, reflecting its ongoing commitment to expanding its product offerings and market presence.